scispace - formally typeset
E

Everson Nogoceke

Researcher at Hoffmann-La Roche

Publications -  24
Citations -  1397

Everson Nogoceke is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Macular degeneration & Type 2 diabetes. The author has an hindex of 12, co-authored 24 publications receiving 910 citations. Previous affiliations of Everson Nogoceke include Polish Academy of Sciences & University of Dundee.

Papers
More filters
Journal ArticleDOI

Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future

Johanna M. Colijn, +151 more
- 14 Jul 2017 - 
TL;DR: A decreasing prevalence of AMD and an improvement in visual acuity in CNV occuring over the past 2 decades in Europe is observed and healthier lifestyles and implementation of anti–vascular endothelial growth factor treatment are the most likely explanations.
Journal ArticleDOI

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

TL;DR: RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery, and modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions, making it a potential next‐generation therapy for neovascular indications of the eye.
Journal ArticleDOI

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

TL;DR: The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naïve patients, and the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricIMab for patients with DME is suggested.
Journal ArticleDOI

Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes

TL;DR: These studies enabled the stringent definition of a novel transcriptomic signature of type 2 diabetic islets, regardless of islet source and isolation procedure, which indicates differences possibly due to peculiarities of these hyperglycaemic conditions.